Meth-OD: A Study of IXT-m200 in Patients With Toxicity From Methamphetamine Overdose

Phase 2

Terminated

• Conditions: Methamphetamine Intoxication (Disorder)
• Interventions: Biological: IXT-m200; Drug: Lorazepam; Drug: Haloperidol

• Registration Number: NCT04715230
• Lead Sponsor: InterveXion Therapeutics, LLC

Brief Summary

The hypothesis of this multisite Phase 2a study is that IXT-m200 will be well-tolerated in patients with acute mild to moderate METH toxicity. A randomized, open label design will be used in which one dose of IXT-m200 will be compared to treatment-as-usual (TAU). Approximately 40 participants will be enrolled in 4 cohorts. A dose escalation approach will be used so that progressively higher IXT-m200 doses will be evaluated in each cohort. In conjunction with safety monitoring, this design assures the opportunity to observe early safety findings before any participants are exposed to the next higher dose. The randomization ratio for IXT-m200 versus TAU is defined as 4:1 for each cohort so that the number of participants receiving TAU equals the number receiving each dose of IXT-m200 at the end of the study.

Agitation scales and vital signs will be recorded to track effect of the antibody treatment versus TAU over time on agitation associated with METH use. While in the emergency department (ED), detailed and pertinent medical and psychiatric histories, and physical exam will be obtained, along with laboratory assessments and ECGs. In the ED, participants will give blood samples for analysis of METH and IXT-m200 concentrations and followed for development of adverse events. Participants will be evaluated at 2 days and 4 weeks after discharge from the ED for adverse events and drug use history. Cohort escalation reviews will be performed by the Sponsor, Medical Monitor, and Data and Safety Monitoring Board (DSMB) between cohorts and the next group will not start until after completion of this review.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2021-01-13
• Study First Submitted QC: 2021-01-14
• Study First Posted: 2021-01-20
• Study Start: 2021-06-30
• Primary Completion: 2022-10-05
• Study Completion: 2022-11-14
• Status Verified: 2023-01
• Results First Submitted: 2023-10-02
• Results First Submitted QC: 2023-10-30
• Last Update Submitted: 2023-10-30
• Results First Posted: 2023-11-18
• Last Update Posted: 2023-11-18

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

1. Be aged 18 to 45 years, inclusive;
2. Present to the ED with METH toxicity as defined in protocol;
3. Have a PANSS-EC score of 14-28, inclusive;
4. Have or agrees to have an intravenous (IV) line placed;
5. Give a history of METH use in the past 24 hours, with participant or observer attribution of symptoms to METH, or have a positive METH drug screen;
6. Be accompanied or readily represented by a legally authorized representative (surrogate) who can consent to participation on behalf of the participant; and
7. Assent to participation in the study.

Exclusion Criteria

1. Present with concomitant opioid overdose requiring ventilatory support;

2. Be self-reported to be pregnant or lactating;

3. Be considered to have significant concomitant medical illness or trauma, or symptoms of severe METH toxicity including

   1. sepsis or febrile illness;
   2. myocardial infarction, cardiac decompensation or arrhythmias including tachycardia that is not sinus; severe hypertension (>180/110 mmHg); inadequately treated hypertension on chronic medication; history of vasculitis
   3. coma, stroke or severe head injury; new or ongoing seizure activity
   4. acute pulmonary decompensation or severe chronic obstructive pulmonary disease;
   5. any hepatic impairment and/or acute hepatitis or renal impairment due to concomitant medical illness; or
   6. current, or history of, neuroleptic malignant syndrome

4. Be considered to be at imminent risk of suicide or have disqualifying answers to the following two questions. Disqualifying answers would be 1b2 or 2b. 1. In the past 30 days, have you considered killing yourself? a) No; b) Yes - if Yes, how often? b1) Not often (twice or less), b2) Somewhat often (more than twice). 2. In the past year, have you attempted to kill yourself? a) No; b) Yes;

5. Be considered to be at imminent risk of injury or danger to self, others or property;

6. Have a history of severe allergy (rash, hives, breathing difficulty, etc.), known hypersensitivity or infusion reaction to any antibody medications, lorazepam or haloperidol; or

7. Be judged by the treating ED physician, investigator, or Sponsor (or designee) to be inappropriate for the study, including people whom the investigator determines cannot reasonably be consulted for assent to participation.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
IXT-m200	IXT-m200	IXT-m200 is a high-affinity chimeric anti-METH monoclonal antibody that is well-tolerated in healthy volunteers and in non-intoxicated people with METH use disorder. The total dose will be given over 10 min for the 0.5-g dose and over 20 min for the 1-, 1.5-, and 2-g doses.
Treatment as Usual (TAU)	Lorazepam	Lorazepam is a benzodiazepine that is safe and commonly used to treat agitation and dysphoria in the emergency setting. Haloperidol is commonly used to treat agitation due to psychosis.
Treatment as Usual (TAU)	Haloperidol	Lorazepam is a benzodiazepine that is safe and commonly used to treat agitation and dysphoria in the emergency setting. Haloperidol is commonly used to treat agitation due to psychosis.

Primary Outcome Measures

Name	Time	Method
Number of Patients With Treatment-related AEs as Measured by Clinical Laboratory Testing	3 days	Clinical laboratory testing
Number of Patients With Treatment-related AEs as Measured by Electrocardiogram	4 hours	Electrocardiogram
Number of Patients With Treatment-related AEs as Measured by Physical Examinations	28 days	Physical examinations
Number of Patients With Treatment-related Adverse Events (AEs) as Measured by Vital Signs	28 days	Blood pressure, heart rate, and temperature

Secondary Outcome Measures

Name	Time	Method
Number of Participants at Certain Degrees of Normalization of Blood Pressure Over Time	Baseline and hours 0.5, 1, 2, 3, 4, and 8 post-dose or until discharge.	Blood pressure over time; reported as the number of participants with blood pressure out of normal range (i.e., diastolic \>110 or \<50 mmHg, or systolic \>180 or \<90 mmHg))
Time Course and Degree of Normalization of Agitation	Baseline and hours 0.5, 1, 2, 3, 4, and 8 post-dose or until discharge.	Agitation/sedation scores over time as measured by Agitation/Calmness Evaluation Score (ACES). The minimum value is 1 (highly agitated) and the highest value is 9 (completely sedated). A score of 3-5 is considered normal.
Number of Participants at Certain Degrees of Normalization of Heart Rate Over Time	Baseline and hours 0.5, 1, 2, 3, 4, and 8 post-dose or until discharge.	Heart rate over time reported as number of participants with heart rate high (\>120 beats/min), normal, or low (\<40 beats/min).
Time Course and Degree of Normalization of Temperature	Baseline and hours 0.5, 1, 2, 3, 4, and 8 post-dose or until discharge.	Temperature over time
Number of Participants Requiring Rescue Medications for Psychiatric or Cardiovascular Manifestations of METH Toxicity	8 hours	Number of participants that need rescue medications to treat: * agitation, dysphoria, or psychosis (central nervous system toxicity); * hypertension, tachycardia, or other cardiovascular instability (cardiovascular toxicity)

Trial Locations

Locations (4)

University of Arkansas for Medical Sciences; 🇺🇸 Little Rock, Arkansas, United States

Sacred Heart Medical Center; 🇺🇸 Spokane, Washington, United States

University of New Mexico Hospital; 🇺🇸 Albuquerque, New Mexico, United States

Providence Regional Medical Center Everett; 🇺🇸 Everett, Washington, United States